BTK Inhibitors: An Emerging Target in Multiple Sclerosis 

Target Audience
This educational activity has been designed to meet the needs of neurologists, primary care physicians, nurse practitioners, physician assistants, and other advanced health care professionals who manage patients with MS.

Program Overview
Multiple sclerosis (MS) is a chronic inflammatory condition that affects approximately 1 million US adults. The disease is marked by central nervous system (CNS) demyelination that results in fatigue, spasticity, and pain, among many other symptoms that negatively impact quality of life. Appreciation for the need to prevent increasing CNS damage and disability accumulation in patients with MS continues to drive efforts to identify new disease-modifying therapies with the potential for greater efficacy and long-term safety. Among the new candidates are multiple Bruton's tyrosine kinase (BTK) inhibitors, which exert their therapeutic effects by targeting B-cell receptor signaling.

Join our esteemed clinician faculty for a review of the clinical rationale for BTK inhibition in MS treatment, and the efficacy and safety of BTK inhibitor therapies currently in late-stage development. The program will conclude with an interactive mechanism of action activity and access to a downloadable resource.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Improve knowledge of clinicians on the role of BTK inhibition in MS management
Describe the mechanisms of action for emerging BTK inhibitors
Recall available safety and efficacy data for emerging BTK inhibitors